Literature DB >> 3278476

Endocrine evaluation and therapy of erectile dysfunction.

R D McClure1.   

Abstract

Recent innovative laboratory and clinical investigations have implicated an organic cause for as many as 30 to 50 per cent of cases of impotence. Understanding the clinical subtleties of hypogonadism and the reproductive hormonal axis in the male is critical to the evaluation and treatment of impotence of endocrinologic origin. Gonadotropin assays are essential for detecting elevations of FSH and LH, which will help to distinguish primary from secondary testicular failure. The goal of androgen replacement is the maintenance of physiologic testosterone levels without the potential hepatotoxic effects.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3278476

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  4 in total

Review 1.  The effects of testosterone on the cavernous tissue and erectile function.

Authors:  R Shabsigh
Journal:  World J Urol       Date:  1997       Impact factor: 4.226

Review 2.  Androgen replacement in men with hypogonadism and erectile dysfunction.

Authors:  Marion Albrecht-Betancourt; Rabih A Hijazi; Glenn R Cunningham
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

Review 3.  Pharmacological management of erectile dysfunction.

Authors:  F Montorsi; G Guazzoni; P Rigatti; G Pozza
Journal:  Drugs       Date:  1995-09       Impact factor: 9.546

4.  A relationship of sex hormone levels and erectile dysfunction: which tests should be done routinely?

Authors:  Talha Müezzinoğu; Bilal Gümüş; Gökhan Temeltaş; Zeki Ari; Coşkun Büyüksu
Journal:  Yonsei Med J       Date:  2007-12-31       Impact factor: 2.759

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.